Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07541469
Rezdiffra Pregnancy and Lactation Registry
Sponsor: Madrigal Pharmaceuticals, Inc.
View on ClinicalTrials.gov
Summary
To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
Official title: A Phase 4, Decentralized Observational Registry to Evaluate the Safety in Women With NASH and Their Infants Exposed to REZDIFFRA™ (Resmetirom) During Pregnancy and/or Lactation
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
10
Start Date
2026-03-04
Completion Date
2030-04-08
Last Updated
2026-04-21
Healthy Volunteers
Yes
Interventions
DRUG
Rezdiffra
Exposure to at least one dose of Resmetirom.
Locations (1)
Madrigal Pharmaceuticals
West Conshohocken, Pennsylvania, United States